STOCK TITAN

Precigen Inc - PGEN STOCK NEWS

Welcome to our dedicated news page for Precigen (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Precigen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Precigen's position in the market.

Rhea-AI Summary
Precigen, Inc. (Nasdaq: PGEN) announced clinical data from the pivotal Phase 2 study of PRGN-2012 AdenoVerse immunotherapy for recurrent respiratory papillomatosis will be presented at the 2024 ASCO Annual Meeting. The therapy shows promising complete and durable responses in patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
conferences clinical trial
-
Rhea-AI Summary
Actym Therapeutics, a company focusing on a new drug modality for treating solid tumors, appoints Thomas Smart as the Chief Executive Officer. With 25 years of experience in the biopharmaceutical industry, Mr. Smart brings expertise in corporate development, strategic planning, and R&D translation. His appointment comes as Actym gears up for the clinical evaluation of its lead candidate, ACTM-838, showcasing a novel approach through the STACT platform at upcoming conferences. Smart's leadership aims to drive corporate growth, expand the pipeline, and maximize the therapeutic potential of ACTM-838.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
management
-
Rhea-AI Summary
Precigen, Inc. partners with RRPF to launch RRP Awareness Day™ on June 11th, 2024, aiming to raise awareness for the rare HPV-driven disease with no FDA-approved therapeutic.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
none
Rhea-AI Summary
Precigen, Inc. (Nasdaq: PGEN) announces significant progress in developing PRGN-2012 AdenoVerse immunotherapy for RRP, with FDA designations and a BLA submission planned in 2024. Financially, the company has $62.9 million in cash, reduced SG&A costs, and strategic focus on commercial readiness for 2025 launch.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Precigen, Inc. (PGEN) will be discussing their investigational PRGN-2012 AdenoVerse™ immunotherapy for recurrent respiratory papillomatosis in a virtual fireside chat hosted by Cantor Fitzgerald. Participants include key figures such as the CEO and Principal Investigator. Precigen focuses on gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
conferences
-
Rhea-AI Summary
Precigen, Inc. (Nasdaq: PGEN) will report Q4 and full year 2023 financial results on March 19, 2024. The company focuses on gene and cell therapies for various diseases. A conference call will discuss financials and business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
Rhea-AI Summary
Precigen, Inc. (Nasdaq: PGEN) announced that its President and CEO, Helen Sabzevari, PhD, will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The company presentation will take place on February 13, 2024. Precigen is a biopharmaceutical company specializing in gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.5%
Tags
conferences
-
Rhea-AI Summary
Precigen, Inc. (Nasdaq: PGEN) has received Orphan Drug Designation from the European Commission for its investigational medicine PRGN-2012 to treat recurrent respiratory papillomatosis (RRP), a rare and difficult-to-treat neoplastic disease caused by human papillomavirus type 6 or 11. The designation provides regulatory, financial, and commercial incentives, and the company is working to expand the therapy to the EU. PRGN-2012 has shown significant clinical benefit in the Phase 1 study, with 50% of patients remaining surgery-free after more than two years following treatment. The company is preparing for a potential launch in the United States in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.38%
Tags
-
Rhea-AI Summary
Precigen, Inc. (Nasdaq: PGEN) released highlights of pipeline updates, including the anticipated Phase 2 pivotal study data for PRGN-2012 in recurrent respiratory papillomatosis (RRP) and plans for a BLA submission under an accelerated approval pathway in the second half of 2024. The Company is actively preparing for commercial readiness for a potential launch in 2025. PRGN-2012 is an investigational off-the-shelf AdenoVerse immunotherapy designed for the treatment of RRP and has shown strong efficacy and a favorable safety profile in Phase 1 trials. The Company is also advancing its PRGN-2009 in OPSCC and Cervical Cancer and UltraCAR-T clinical programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
none
Rhea-AI Summary
Precigen, Inc. (Nasdaq: PGEN) announced that President and CEO, Helen Sabzevari, PhD, will present a corporate and clinical overview at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The company focuses on developing innovative gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases, aiming to advance medicine with precision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
conferences
Precigen Inc

Nasdaq:PGEN

PGEN Rankings

PGEN Stock Data

353.46M
122.48M
11.72%
64.45%
6.79%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Germantown

About PGEN

precigen, inc. discovers and develops the next generation of gene and cellular therapies in the united states. it also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. in addition, the company offers ultravector platform that incorporates advanced dna construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbil15, a gene that enhances functional characteristics of immune cells; sleeping beauty, a non-viral transposon/transposase system; attsite recombinases, which breaks and rejoins dna at specific sequences; adenoverse technology platform, a library of engineered adenovector serotypes; and l. lactis is a food-grade bacterium. additionally, it provides rheoswitch inducible gene switch that provides qua